about
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients.Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial.Adjusting for covariates in non-inferiority studies with margins defined as risk differences.Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes.The Cost-Effectiveness of Bevacizumab in Advanced Ovarian Cancer Using Evidence from the ICON7 Trial.Impact of retrospective data verification to prepare the ICON6 trial for use in a marketing authorization application
P50
Q34520190-33F2631C-7B08-4730-9EBD-BF805EBAA72AQ36287626-EE76723B-C5A3-4C7A-9C66-EA60DDF5062CQ37672829-065ED83F-69E8-4501-BDB3-0A83D82E7FE3Q38879397-5032BE1B-AF0A-40EA-B185-7D67649EC18FQ42618116-3E4C26A7-6D71-4A93-B024-E42FE677034CQ46083075-D9EE8F2C-B2B6-4C3A-B188-3AA06C6610E9Q47764566-F4E8396E-211A-4226-AE64-F8716CDAA050Q92196101-E369327A-FEE4-4761-8D3C-5FBE64AED914
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Andrew Embleton
@ast
Andrew Embleton
@en
Andrew Embleton
@es
Andrew Embleton
@nl
type
label
Andrew Embleton
@ast
Andrew Embleton
@en
Andrew Embleton
@es
Andrew Embleton
@nl
prefLabel
Andrew Embleton
@ast
Andrew Embleton
@en
Andrew Embleton
@es
Andrew Embleton
@nl
P106
P1153
53871367200
P21
P31
P496
0000-0001-9402-8132